Skip to main content
. 2019 Jul 26;70(12):2695–2702. doi: 10.1093/cid/ciz693

Figure 2.

Figure 2.

Incidence of reinfection in the PREVAIL extension study. Risk factors for reinfection among all participants in the extension study (n = 114) were ongoing IDU in the follow-up period (P < .001), a lack confidence in the ability to avoid contracting HCV (P < .001), homelessness (P = .002), and living with someone who injects drugs (P = .007). Abbreviations: HCV, hepatitis C virus; IDU, injection drug use; PREVAIL, Prevent Resistance Eliminate Virus and Improve Life.